AnGes MG, Inc. is a biopharmaceutical company founded December 1999 based on an innovative discovery by researchers of Osaka University. We specialize in R&D and practical application of genetic medicine. At present, we are engaged in developing two new medicines: the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and NFkB decoy which controls various inflammations. We are also making every effort to develop the HVJ Envelope Vector(a new delivery technology for medicines) through our subsidiary, GenomIdea Inc. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL). We are as determined as ever to continue our efforts to satisfy the expectations of patients and families who await new drugs, as well as those of shareholders, investors, and society as a whole.